Skip to main content
Clinical Trials/NCT06545253
NCT06545253
Not yet recruiting
Not Applicable

A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants

IRCCS Ospedale San Raffaele0 sites60 target enrollmentAugust 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
USH2A Variant Retinitis Pigmentosa
Sponsor
IRCCS Ospedale San Raffaele
Enrollment
60
Primary Endpoint
Clinical relevance of microRNAs in USH2A-RP
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Aim of the study is to perform a non-invasive multimodal retinal imaging investigation in a cohort of patients affected by USH2A retinitis pigmentosa (USH2A-RP), in order to develop a new diagnostic paradigm to categorize clinically relevant subgroups. All the procedures will be performed according to normal clinical practice. In addition, a novel quantitative profiling of serum microRNAs will be carried out in order to analyze the clinical importance of microRNA biomarkers in the clinical setting of the disease.

Registry
clinicaltrials.gov
Start Date
August 2024
End Date
February 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
IRCCS Ospedale San Raffaele
Responsible Party
Principal Investigator
Principal Investigator

Maria Lucia Cascavilla

Co-Principal Investigator

IRCCS Ospedale San Raffaele

Eligibility Criteria

Inclusion Criteria

  • age \>18 years
  • genetically confirmed diagnosis of USH2A-RP
  • availability of genetic tests to assess the pathogenic variants

Exclusion Criteria

  • inability to understand and sign the written informed consent form
  • any inflammatory, infectious or degenerative eye disease
  • media opacities resulting incompatible with good imaging quality
  • uncontrolled systemic, metabolic, autoimmune neuroinflammatory and neurodegenerative disease
  • ophthalmologic surgery within the previous six months

Outcomes

Primary Outcomes

Clinical relevance of microRNAs in USH2A-RP

Time Frame: 6 months period following the last follow-up visit

For all patients enrolled, at baseline, peripheral blood sampling will be collected.

Secondary Outcomes

  • To test the association between specific microRNAs profiles and the quantitative multimodal retinal imaging findings(6 months period following the last follow-up visit)

Similar Trials